CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Sung-Bae Kim, In-Gu Do, Janice Tsang, Tae-You Kim, Yoon-Sim Yap, Gerardo Cornelio, Gyungyub Gong, Soonmyung Paik, Suee Lee, Ting-Ying Ng, Sarah Park, Ho-Suk Oh, Joanne Chiu, Joohyuk Sohn, Moonhee Lee, Young-Jin Choi, Eun Mi Lee, Kyong-Hwa Park, Christos Nathaniel, Jungsil Ro
Cancer Research and Treatment. 2019;51(4):1527-1539.   Published online 2019 June 4    DOI: https://doi.org/10.4143/crt.2018.598

Excel Download

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Cancer Research and Treatment. 2019;51(4):1527-1539   Crossref logo
Link1 Link2 Link3

First-Line Efficacy of Anti-HER2 Treatments in Previously Treated HER2-Positive Metastatic Breast Cancer Patients: A Retrospective Observational Study Investigating the Efficacy of Re-Exposure to Anti-HER2 Therapy for HER2-Positive Metastatic Breast Cancer Patients in Comparison with Naïve Patients
Breast Care. 2021;1-7   Crossref logo
Link1 Link2

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study
Breast Cancer. 2013;22(2):192-200   Crossref logo
Link1 Link2 Link3

HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
Breast Cancer Research and Treatment. 2019;175(1):261-261   Crossref logo
Link1 Link2 Link3

Title Does Definitive Local Therapy Offer Cure in Select HER2+ De Novo Metastatic Breast Cancer Patients Treated with Dual Anti-HER2 Blockade?
. 2021;   Crossref logo
Link1 Link2

Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
AboutOpen. 2018;4(1):162-165   Crossref logo
Link1 Link2

Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
Breast Cancer Research and Treatment. 2021;187(3):815-830   Crossref logo
Link1 Link2 Link3

HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy
AboutOpen. 2018;4(1):59-61   Crossref logo
Link1 Link2

Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cells
European Journal of Cancer. 2017;72:S40   Crossref logo
Link1 Link2

194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer
Molecular Therapy. 2012;20:S77   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.